Allogeneic Left Atrial and Pulmonary Vein Transplant for Pulmonary Vein Stenosis



Status:Recruiting
Healthy:No
Age Range:Any - 17
Updated:10/24/2018
Start Date:September 13, 2018
End Date:September 2022
Contact:Breanna Piekarski, RN, BSN
Email:breanna.piekarski@cardio.chboston.org
Phone:617-919-4457

Use our guide to learn which trials are right for you!

This is a prospective, single center, safety and feasibility trial to evaluate the
transplantation of the left atrium and pulmonary veins in patients with pulmonary vein
stenosis. Consented patients will be listed for transplantation. Once a suitable donor has
been identified, the left atrium, pulmonary veins and complete lung block will be harvested
from the donor and transported to Boston Children's Hospital as is the procedure for routine
lung transplantation patients. The left atrium and pulmonary veins will be transplanted into
the recipient. The recipient will receive the normal immunosuppression protocol used for
heart transplantation.

This pilot study will include 5 patients.

Techniques for harvest of the posterior left atrium and pulmonary veins from a suitable organ
donor have been well established as this is currently accomplished during every harvest of
lungs for lung transplantation. The difference in this therapy is that the lung parenchyma
will not be utilized. However, the harvest from the donor will be exactly the same with the
full lung block typically harvested for lung transplant removed and transported back to the
site of implantation. The exact extent of pulmonary vein utilization from the lung block will
be determined at the time of implantation based on the exact anatomy and location of the
pulmonary vein disease of the recipient.

As this represents a new transplantation approach, this program has been discussed with the
United Network for Organ Sharing (UNOS) and the New England Organ Bank (NEOB). UNOS
identified this as a new area of transplantation related to but separate from heart or lung
transplantations. Eventually if this progresses to a national phase, it will require creation
of a new patient waiting list and all the policies that accompany a new area of
transplantation. Although there is enthusiasm at UNOS for this approach, they recommended
that it be pursued as a regional research program as an initial step. The NEOB also has
voiced support for this program in a meeting with them including their medical director. They
are interested in supporting this program as a Region 1 research program and will perform a
full evaluation for approval once local IRB approval has been granted. The Children's team
will work closely with NEOB to create a list of potential patients and identify suitable
donors.

Utilizing standardized harvesting techniques will minimize any changes to the current harvest
approach and definition of tissue allocation during the harvest procedure. As the lung
parenchyma is unnecessary, it is expected that suitable donors for left atrial transplant
would come from two sources:

- The first source is brain dead donors in whom the lungs are not allocated for
transplantation based on rejection of the lungs for quality or no matching donors.

- The second source is donors after cardiac death (DCD) which are utilized in the adult
population for kidney, liver and lung transplantation. DCD organs are not currently
utilized pediatric lung transplantation. However, as the viability of these tissues,
including the entire lung block is well established, these represent a potential donor
pool for left atrial transplant patients.

Certainly experience with preservation of the kidney grafts for hours or days with integrated
perfusion systems has demonstrated the successful implantation of vascularized tissues
appropriately preserved can be extended beyond the traditional four hour window targeted for
lung transplantation. Kidney transplants are commonly done within 24 hours without evidence
of impact on the vascular patency these grafts. In addition, only vascular tissue is being
transplanted that has no effect on gas exchange or contractility. Accordingly it is expected
that the goal implantation time for left atrial transplants after harvest will not need to be
within the four to six hour window used for lung transplant but can be safely extended to 24
hours. This window extends the donor pool for left atrial transplants to the entire country.

Excision of recipient left atrium and stenotic pulmonary veins and implantation of left
atrial graft The set up for the operation will be identical to all major cardiopulmonary
bypass cardiac cases. The surgical approach for the recipient will likely be a clamshell
incision that crosses the sternum in the fourth interspace. This is the same incision used
for lung transplant. The patient will be cannulated for cardiopulmonary bypass in the distal
aorta, SVC and low in the IVC. Cardiopulmonary bypass will be initiated and the patient will
be cooled to 18°C. Prior to arresting the heart, the donor left atrium and pulmonary veins
will be inspected in the lung block. The pulmonary veins from the donor will be mobilized and
prepared for resection from the lung block.

The cross clamp will be applied and the heart arrested. The pulmonary veins of the recipient
will be mobilized and transected beyond the level stenoses. The left atrium and pulmonary
vein graft then be brought to the field and positioned in the orthotopic position.

The anastomosis of the pulmonary veins will be completed with a generous diameter of the
anastomotic area to minimize any risk of late anastomotic narrowing even in the smallest of
pulmonary vein segments. The donor left atrium will be anastomosed to the posterior left
atrial cuff of the heart. Only the affected pulmonary veins with stenosis will be
transplanted. This may be one or up to all 4 main pulmonary veins. If an individual pulmonary
vein or side of pulmonary veins are unaffected, they will not have any manipulation or
intervention on them. A formal atrial fenestration will be created. Post-bypass evaluation
with transesophageal echocardiogram will assess pulmonary vein velocities and flow. The chest
will be closed and patient transferred intubated to the ICU.

In the initial clinical experience with these transplants, a traditional immunosuppression
protocol for heart transplants will be followed. Over time new protocols will be developed
and tested which focused on minimizing the long-term immunosuppression regimens.

Inclusion Criteria:

- Pulmonary vein stenosis involving at least one but up to all of the main pulmonary
veins following initial treatment, including but not limited to balloon dilation,
stenting, surgical repair or chemotherapy

- Focal pulmonary stenosis limited to the main pulmonary veins or their first or second
order branches.

Exclusion Criteria:

- Diffuse pulmonary vein stenosis involving long segments of one or more pulmonary veins
including diffuse stenosis into the second order pulmonary vein branches or beyond

- Significant underlying lung disease

- Irreversible pulmonary artery hypertension exceeding indexed 10 Woods units (WU)

- Irreversible multisystem organ failure; or additive effects of multiple systems
affected making transplant survival unlikely

- Progressive systemic disease with early mortality (genetic/metabolic, idiopathic,
syndromic)

- Morbid obesity (BMI>30)

- Diabetes mellitus with evidence of end-organ damage

- Severe chromosomal, neurologic or syndromic abnormalities

- Active infection

- HIV or chronic hepatitis B or C infection

- Severe left ventricular dysfunction

- Malignancy within 5 years prior to transplant

- Severe renal or liver failure

- Inadequate social support for post-transplant management

- Recent history of illicit drug, tobacco or alcohol abuse despite trials/assistance to
stop behavior

- Episode of acute rejection within the previous 6 months

- Post-transplant lymphoproliferative disease that has been within two years

- Evidence of large stroke with high risk for hemorrhagic conversion
We found this trial at
1
site
300 Longwood Ave
Boston, Massachusetts 02115
(617) 355-6000
Principal Investigator: David Hoganson, MD
Phone: 617-919-4457
Boston Children's Hospital Boston Children's Hospital is a 395-bed comprehensive center for pediatric health care....
?
mi
from
Boston, MA
Click here to add this to my saved trials